THZ1, a covalent CDK7/12/13 inhibitor, exerts antitumor activity through transcriptional regulation by inhibiting CDK7 in acute T cell leukemia, MYCN-amplified neuroblastoma, small cell lung cancer, and triple-negative breast cancer (169–172). Here, CDK7 is linked to T-cell acute lymphoblastic leukemia.